BRAIN Biotech AG (BNN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BRAIN Biotech AG (BNN) has a cash flow conversion efficiency ratio of -2.326x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-4.28 Million ≈ $-5.01 Million USD) by net assets (€1.84 Million ≈ $2.15 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BRAIN Biotech AG balance sheet quality to measure how much of total assets are equity-financed.
BRAIN Biotech AG - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how BRAIN Biotech AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check BNN cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
BRAIN Biotech AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BRAIN Biotech AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Futuretech II Acquisition Corp
NASDAQ:FTII
|
-3.681x |
|
Anson Resources Ltd
AU:ASN
|
-0.058x |
|
Bina Puri Holdings Bhd
KLSE:5932
|
-0.332x |
|
Linz Textil Holding AG
VI:LTH
|
0.058x |
|
HeiTech Padu Bhd
KLSE:5028
|
-0.771x |
|
Advani Hotels & Resorts (India) Limited
NSE:ADVANIHOTR
|
0.016x |
|
Latitude Tree Holdings Bhd
KLSE:7006
|
0.021x |
|
Polychem Indonesia Tbk
JK:ADMG
|
-0.015x |
Annual Cash Flow Conversion Efficiency for BRAIN Biotech AG (2012–2025)
The table below shows the annual cash flow conversion efficiency of BRAIN Biotech AG from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see BRAIN Biotech AG (BNN) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | €1.84 Million ≈ $2.15 Million |
€-9.23 Million ≈ $-10.79 Million |
-5.015x | -1843.65% |
| 2024-09-30 | €13.89 Million ≈ $16.23 Million |
€-3.58 Million ≈ $-4.19 Million |
-0.258x | -40.78% |
| 2023-09-30 | €23.01 Million ≈ $26.91 Million |
€-4.22 Million ≈ $-4.93 Million |
-0.183x | -322.69% |
| 2022-09-30 | €34.25 Million ≈ $40.04 Million |
€-1.49 Million ≈ $-1.74 Million |
-0.043x | +53.57% |
| 2021-09-30 | €41.83 Million ≈ $48.90 Million |
€-3.91 Million ≈ $-4.57 Million |
-0.093x | +48.79% |
| 2020-09-30 | €26.14 Million ≈ $30.56 Million |
€-4.77 Million ≈ $-5.57 Million |
-0.182x | +7.80% |
| 2019-09-30 | €17.09 Million ≈ $19.98 Million |
€-3.38 Million ≈ $-3.95 Million |
-0.198x | -11.84% |
| 2018-09-30 | €30.64 Million ≈ $35.82 Million |
€-5.42 Million ≈ $-6.33 Million |
-0.177x | -45.48% |
| 2017-09-30 | €47.36 Million ≈ $55.37 Million |
€-5.76 Million ≈ $-6.73 Million |
-0.122x | +62.31% |
| 2016-09-30 | €26.93 Million ≈ $31.48 Million |
€-8.68 Million ≈ $-10.15 Million |
-0.322x | +54.88% |
| 2015-09-30 | €5.76 Million ≈ $6.73 Million |
€-4.11 Million ≈ $-4.81 Million |
-0.715x | -153.56% |
| 2014-09-30 | €13.85 Million ≈ $16.19 Million |
€-3.90 Million ≈ $-4.56 Million |
-0.282x | -2.26% |
| 2013-09-30 | €17.59 Million ≈ $20.57 Million |
€-4.85 Million ≈ $-5.67 Million |
-0.276x | +43.22% |
| 2012-09-30 | €12.12 Million ≈ $14.17 Million |
€-5.89 Million ≈ $-6.88 Million |
-0.485x | -- |
About BRAIN Biotech AG
BRAIN Biotech AG provides bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates through two segments: BRAINBiocatalysts and BRAINBioIncubator. The BRAINBiocatalysts segment develops, produces, and distributes specialty enzymes, microorganisms, and ingredients. The BRAINBioIncubator segment encompasses a pipeline of re… Read more